广州领晟医疗科技有限公司，Link  Health  Group（以下简称“领晟医药”）成立于2012年，注册资本1063.83万元，国家高新技术企业，坐落于广州市科学城，是一家致力于创新药物研发和国际技术引进的新型医药企业。
通过不断努力，目前领晟医药已完成多层项目储备，覆盖临床前到临床阶段多个新药品种。主要集中在肿瘤，骨科，消化科、炎症以及疫苗等领域。我们的业务包括与跨国医药公司、海外专业医药公司、全球领先研发机构等合作，通过专利药物的授权引进新药项目，自主研发新剂型，合作国际多中心临床试验，通过合资公司，战略联盟等形式进行学术推广以及销售等。 领晟医疗目前在欧美有超过20家合作企业，我们仍然不断在欧美开拓新合作与新业务。
作为一家发展快速的新技术企业，具有开拓精神的团队，优质的人才是我们领晟发展的动力和基石。 我们欢迎有能力有激情，有致从事创新药物开发的您加入。
公司网站：http://www.healthinlink.com/ 

Link Health is a company located in China focusing on research of innovative medicinal products. Since 2014, Link Health has grown itself into a leading company in China for developing first-in-class new drugs. In the last three years, the company has built a pipeline covering 9 Class 2 New Drugs including both licensed-in and self-developed drug candidates. In which, half have been in clinical stage aboard and half will enter the IND in China before the end of 2017. Link Health has a very dynamic team in rapid growth to support the registration,future plan of FDA file and clinical development in Asia and USA.
For more information, please refer to our website: www.healthinlink.com